NewsBenzingaGuggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7 Guggenheim Initiates Coverage On Ovid Therapeutics with Buy Rating, Announces Price Target of $7 Benzinga 2026.10.05 20:16 (GMT+0) Open on Benzinga Other news A $22.6 Billion Reason Why Autodesk Stock Is Up Today OpenAI will start watermarking ChatGPT’s text in the EU Stocks Settle Higher as Big Tech Rallies Trump Looks Set to Give Vistra Stock a $4 Billion Boost Etched fields funding offers at $40B+ valuation, sources say Here’s Why I’m Very Skeptical of the META Stock Rally (And You Should Be Too)
